Ischemic stroke and transient ischemic attack
Conditions
Brief summary
• MACE-free survival over a two-year period, measured at 3, 6, 12, 18, and 24 months, with additional follow-up at three years for those enrolled early in the recruitment phase., • Health-Related Quality of Life (HRQoL) measured using the Patient-Reported Outcomes Measurement Information System - Global-10 (PROMIS-10) at 3, 6, 12, 18, and 24 months, with additional follow-up at three years for those enrolled early in the recruitment phase.
Detailed description
Number of new major cardiovascular events, Cognitive function at 12 and 24 months., Falls (number and time to first fall), Frailty status at 12 and 24 months., Functional outcome at 12 and 24 months.
Interventions
DRUGPravastatine Viatris 10 mg Tabletten
DRUGFluvastatine 20 mg PCH
DRUGcapsules
DRUGRosuvastatine Viatris 5 mg Filmtabletten
DRUGSimvastatine Mylan 40 mg
DRUGfilmomhulde tabletten
DRUGAtorvastatine Viatris 10 mg Filmtabletten
Sponsors
Amsterdam UMC Stichting
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • MACE-free survival over a two-year period, measured at 3, 6, 12, 18, and 24 months, with additional follow-up at three years for those enrolled early in the recruitment phase., • Health-Related Quality of Life (HRQoL) measured using the Patient-Reported Outcomes Measurement Information System - Global-10 (PROMIS-10) at 3, 6, 12, 18, and 24 months, with additional follow-up at three years for those enrolled early in the recruitment phase. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of new major cardiovascular events, Cognitive function at 12 and 24 months., Falls (number and time to first fall), Frailty status at 12 and 24 months., Functional outcome at 12 and 24 months. | — |
Countries
Netherlands
Outcome results
None listed